



## SHARP ACCELERATION IN THE GROWTH MOMENTUM

**Q1 2011 SALES: +26.7% TO €293 MILLION**

**2011 ANNUAL SALES GUIDANCE OF AT LEAST €1,210 MILLION REAFFIRMED**

### Puteaux, 4<sup>th</sup> May 2011

ORPEA, a leading player in Long-Term Care (nursing homes), Post-Acute Care and Psychiatric Care, today announced its sales for the first quarter to 31<sup>st</sup> March, 2011.

<i>In €m IFRS</i>	<b>Q1 2011</b>	<b>Q1 2010</b>	<b>Δ</b>
<b>France</b>	<b>261.2</b>	<b>203.6</b>	<b>+28.3%</b>
<i>% of total sales</i>	<i>89%</i>	<i>88%</i>	
<b>International</b>	<b>31.8</b>	<b>27.6</b>	<b>+15.5%</b>
<i>% of total sales</i>	<i>11%</i>	<i>12%</i>	
<b>Belgium</b>	16.4	13.3	
<b>Spain</b>	7.6	7.4	
<b>Italy</b>	5.0	4.3	
<b>Switzerland</b>	2.9	2.6	
<b>Total sales</b>	<b>293.0</b>	<b>231.2</b>	<b>+26.7%</b>
<i>Organic growth</i>			<b>+8.4%</b>

Yves Le Masne, CEO of ORPEA, comments: "In the first quarter of 2011, ORPEA again recorded one of the sector's highest growth rates, with sales increasing by +26.7%.

It should be noted that this strong growth does not take into account the sales recorded by Medibelge, which is 49%-held by ORPEA and is thus accounted for by the equity method.

This acceleration in the upward momentum was the result:

- firstly, of further strong organic growth despite there being no new facilities opened during the first three months of the year, thus reflecting the fact that occupancy rates remain high thanks to the appeal and Quality of ORPEA's facilities;
- and secondly, of the activity of the Mediter group acquired at the end of 2010. Indeed, the operational integration of Mediter's facilities is taking place faster than expected thanks to the experience and know-how of ORPEA's teams in this domain.

The gradual upramping of the facilities resulting from the strategic acquisition of Mediter, the opening of over 2,000 beds over the next ten months and a growth reservoir of more than 9,000 beds provide ORPEA with exceptional short-, medium- and long-term visibility in terms of both growth and solid profitability.

The Group is therefore confidently reaffirming its 2011 sales guidance of at least €1,210 million with further solid profitability."

**Next press release: sales for the 1<sup>st</sup> half of 2011  
19<sup>th</sup> July 2011, before market**

**About ORPEA** ([www.orpea.com](http://www.orpea.com)): Listed on Euronext Paris since April 2002 and a member of the Deferred Settlement Service, the ORPEA group is the leading European player in the Long-Term Care and Post-Acute Care sectors. As of 1<sup>st</sup> March 2011, the Group has a unique European network of healthcare facilities with 33,700 beds (27,862 of them operational) over 364 sites, including:

- 27,014 beds in France: 22,447 operational (including 2,859 being renovated) + 4,567 under construction, spread across 302 sites,
- 6,686 beds in Europe (Spain, Belgium, Italy and Switzerland): 5,415 operational (including 491 being renovated) + 1,271 under construction, spread across 62 sites.

**Listed on Euronext Paris Compartment A** of NYSE Euronext  
Member of the **CAC Mid 60** and **SBF 120** indices - Member of the **SRD**  
ISIN: FR0000184798 - Reuters: **ORP.PA** - Bloomberg: **ORP FP**



**Investor Relations:**

**NewCap.**  
Emmanuel Huynh / Steve Grobet  
Tel: +33 (0)1 44 71 94 94  
[orpea@newcap.fr](mailto:orpea@newcap.fr)

**ORPEA**  
Yves Le Masne  
CEO  
Tel: +33 (0)1 47 75 78 07